Optimization of PEGylated nanoemulsions for improved pharmacokinetics of BCS class II compounds
article
OA: closed
CC0
⤵ 2 in-corpus citations
AI-generated summary
PEGylation of nanoemulsions with DSPE-PEG5000 at 6 mg/mL significantly reduced clearance and increased danazol exposure in rats by shielding droplets from rapid systemic clearance.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The objective of the study was the optimization of nanoemulsion formulations to prevent their rapid systemic clearance after intravenous administration. An amphiphilic PEG derivative DSPE-PEG (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(polyethylene glycol) with different chain lengths and concentration was used as a nanoemulsion droplet surface modifier. The danazol loading in all nanoemulsions was kept on the same level of ∼2 mg/mL. In the present investigation, PEGylated and non-PEGylated nanoemulsions were compared in vitro phagocytosis by incubating with lung macrophages and in vivo after intravenous administration in rats. Danazol-containing nanoemulsions (NE) modified with various PEG chain lengths (2000-10 000) and concentrations (3-12 mg/mL) were prepared and characterized. Nanoemulsion droplets were reproducibly obtained in the size range of 213-340 nm. The non-PEGylated NE had the surface charge of -25.4 mV. This absolute charge value decreased with increasing chain length and concentration. With increase in chain length and density the macrophage uptake decreased which could be due to decrease in surface charge and hydrophilicity of droplets. The greatest shielding of the NE droplets was reached with DSPE-PEG5000 at the concentration of 6 mg/mL where the surface charge changed to -1.27 mV. Following intravenous administration a maximum danazol exposure (401 ± 68.2 h ng/mL) was observed with the lowest clearance rate (5.06 ± 0.95 L/h/kg) from 6 mg/mL DSPE-PEG5000 nanoemulsion. PEG5000 and PEG10000 altered the pharmacokinetic of danazol by decreasing clearance and volume of distribution which is likely explained by the presence of hydrophilic shields around the droplets that prevent their rapid systemic clearance and tissue partitioning.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (2)
- Relative bioavailability of danazol in dogs from liquid-filled hard gelatin capsules 1999
- Evaluation of a Nanoemulsion Formulation Strategy for Oral Bioavailability Enhancement of Danazol in Rats and Dogs 2013
Cited by (2)
References (30)
- Evaluation of a Nanoemulsion Formulation Strategy for Oral Bioavailability Enhancement of Danazol in Rats and Dogs via openalex
- Relative bioavailability of danazol in dogs from liquid-filled hard gelatin capsules via openalex
- doi:10.1016/j.colsurfb.2009.04.017 via openalex
- doi:10.1016/s0939-6411(98)00038-1 via openalex
- doi:10.1016/0014-5793(90)81016-h via openalex
- doi:10.1166/jnn.2010.1738 via openalex
- doi:10.1016/j.phrs.2010.03.005 via openalex
- W2150135298 via openalex
- W2413410958 via openalex
- W4285719527 via openalex
- doi:10.1021/js970184o via openalex
- doi:10.1038/nrd1632 via openalex
- doi:10.1002/jps.2600830432 via openalex
- doi:10.1016/j.ijpharm.2005.10.010 via openalex
- doi:10.3762/bjnano.1.2 via openalex
- doi:10.1007/s11095-007-9284-6 via openalex
- doi:10.4103/0975-8453.59509 via openalex
- doi:10.1002/jps.20627 via openalex
- doi:10.1016/s0031-6997(24)01494-7 via openalex
- doi:10.1007/s11095-011-0510-x via openalex
- doi:10.1080/07315724.2009.10719778 via openalex
- doi:10.1007/s10856-009-3746-9 via openalex
- doi:10.1023/b:pham.0000016235.32639.23 via openalex
- doi:10.1016/s0090-9556(24)02982-9 via openalex
- doi:10.1111/j.1751-1097.1994.tb05083.x via openalex
- doi:10.2174/156720107780362294 via openalex
- doi:10.1016/j.addr.2007.10.013 via openalex
- doi:10.2147/ijn.s47708 via openalex
- doi:10.1016/s0024-3205(01)01392-3 via openalex
- doi:10.1023/a:1016274801930 via openalex
Cited by (2)
Source provenance
- openalex
- last seen: 2026-05-11T06:35:44.859312+00:00
License: CC0
· commercial use OK